|
Aug 28
|
Denmark’s Top Pension Fund Buys Weight-Loss Stocks After Run-Up
|
|
Aug 28
|
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
|
|
Aug 28
|
Five alternatives to Mag 7 stocks if you missed out on Nvidia
|
|
Aug 27
|
Eli Lilly Halves Zepbound Price In New Version Of Weight-Loss Drug
|
|
Aug 27
|
Eli Lilly Offers a Cheaper Form of Zepbound. Why Hims & Hers Stock Is Falling.
|
|
Aug 27
|
Zepbound and Other Weight-Loss Drugs Get More Good News. Why It’s Too Soon to Celebrate.
|
|
Jul 30
|
DexCom Stock Plunged Over 40% Last Week. Are Eli Lilly's and Novo Nordisk's Drugs to Blame?
|
|
Jul 29
|
Novo Nordisk (NVO) Surpasses Market Returns: Some Facts Worth Knowing
|
|
Jul 29
|
Wall Street is still jittery on GLP-1s
|
|
Jul 29
|
What Will Be the Best Weight Loss Drug Stock of 2030: Eli Lilly, or Novo Nordisk?
|
|
Jul 29
|
Weight Loss Drug Stocks Just Took a Hit. Should You Buy the Stock That Caused It?
|
|
Jul 29
|
Swiss pharma giant Roche is ‘fast-tracking’ development of an experimental Wegovy challenger pill for weight loss
|
|
Jul 29
|
Zacks Market Edge Highlights: LLY and NVO
|
|
Jul 28
|
This Could Send Ozempic's Sales Potential to a Whole Other Level
|
|
Jul 27
|
Novo Nordisk's Next-Gen Diabetes Candidate Could Challenge Ozempic -- Is the Stock a Buy?
|
|
Jul 26
|
June PCE inflation print, auto earnings: Morning Brief
|
|
Jul 26
|
EMA backs Wegovy cardiovascular label update as Novo seeks EU coverage
|
|
Jul 26
|
Is Eli Lilly's Stock in a Bubble?
|
|
Jul 26
|
EU approves Novo Nordisk's Wegovy for heart, stroke treatment
|
|
Jul 26
|
Should You Invest in Novo Nordisk (NVO) Ahead of Q2 Earnings?
|